Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A New Cellular Immunotherapy for the Treatment of Multiple Myeloma without Development of Graft-Versus-Host Disease

Michael A Firer, PhD, Sofi Yado, BSc, MSc, Luboshits Galia, PhD, Reuven Or, MD

Blood (2018) 132 (Supplement 1): 3339.

https://doi.org/10.1182/blood-2018-99-110292

Published: 2018

Journal Articles

The Impact of Allogeneic Stem Cell Transplantation As Part of First Line Treatment on Outcome of Patients with Multiple Myeloma Depends on the Method of Analysis

Raynier Devillier, MD, Jurjen Versluis, MD, Bronno Van der Holt, PhD, Marie Jose Kersten, MD PhD, Reinier Raymakers, MD PhD, Sonja Zweegman, MD PhD, Gerard M.J. Bos, MDPhD, Nicolaas PM Schaap, Annemiek Broyl, Pieter Sonneveld, MD, Henk Lokhorst, Jan J. Cornelissen, MD PhD

Blood (2014) 124 (21): 1209.

https://doi.org/10.1182/blood.V124.21.1209.1209

Published: 2014

Journal Articles

Increased Frequencies Of Myeloid-Derived Suppressor Cells and Regulatory T-Cells Decrease Response To Donor Lymphocyte Infusions, Independent Of Graft Versus Host Disease In Multiple Myeloma

Laurens E. Franssen, MD, Maarten E. Emmelot, BSc, Niels W.C.J. van de Donk, MD, PhD, Henk Lokhorst, Tuna Mutis, MD, PhD

Blood (2013) 122 (21): 2005.

https://doi.org/10.1182/blood.V122.21.2005.2005

Published: 2013

Journal Articles

Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing

Niels W.C.J. van de Donk, MD, PhD, Henk M. Lokhorst, MD, Maarten Emmelot, Tineke Aarts-Riemens, Douglas W. McMillin, PhD, Gullu Gorgun, PhD, Steffen Klippel, PhD, Eugen Dhimolea, PhD, Jana Jakubikova, PhD, Catriona A. Hayes, MD, Panisinee Lawasut, MD, Jake E Delmore, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Constantine S. Mitsiades, MD, PhD, Tuna Mutis, MD PhD

Blood (2011) 118 (21): 1838.

https://doi.org/10.1182/blood.V118.21.1838.1838

Published: 2011

Journal Articles

Host Dendritic Cell Vaccinations Combined with Donor Lymphocyte Infusions Induce Host and KLH Specific Immunity in Multiple Myeloma Patients.

Evelien Kneppers, Monique C. Minnema, MD, PhD, Tineke Aarts, Maarten E. Emmelot, Ineke Slaper-Cortenbach, PhD, Kasper Westinga, Tuna Mutis, MD, PhD, Henk M. Lokhorst, MD, PhD

Blood (2009) 114 (22): 2875.

https://doi.org/10.1182/blood.V114.22.2875.2875

Published: 2009

Journal Articles

Polychemotherapy in Combination with Thalidomide Followed by Autologous or Allogeneic Transplantation for Rescue after Autograft or Induction Therapy Failure in Patients with Multiple Myeloma.

Ute Hegenbart, MD, Stefan O. Schonland, MD, Thomas Moehler, MD, Axel Benner, PhD, Sabine Gerull, MD, Martin Goerner, MD, Hans-Joerg Schaefer, MD, Gerlinde Egerer, MD, Peter Dreger, MD, Anthony D. Ho, MD, Hartmut Goldschmidt, MD

Blood (2006) 108 (11): 3018.

https://doi.org/10.1182/blood.V108.11.3018.3018

Published: 2006

NARROW

A New Cellular Immunotherapy for the Treatment of Multiple Myeloma without Development of Graft-Versus-Host Disease

The Impact of Allogeneic Stem Cell Transplantation As Part of First Line Treatment on Outcome of Patients with Multiple Myeloma Depends on the Method of Analysis

Increased Frequencies Of Myeloid-Derived Suppressor Cells and Regulatory T-Cells Decrease Response To Donor Lymphocyte Infusions, Independent Of Graft Versus Host Disease In Multiple Myeloma

Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing

Host Dendritic Cell Vaccinations Combined with Donor Lymphocyte Infusions Induce Host and KLH Specific Immunity in Multiple Myeloma Patients.

Polychemotherapy in Combination with Thalidomide Followed by Autologous or Allogeneic Transplantation for Rescue after Autograft or Induction Therapy Failure in Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

A New Cellular Immunotherapy for the Treatment of Multiple Myeloma without Development of Graft-Versus-Host Disease

The Impact of Allogeneic Stem Cell Transplantation As Part of First Line Treatment on Outcome of Patients with Multiple Myeloma Depends on the Method of Analysis

Increased Frequencies Of Myeloid-Derived Suppressor Cells and Regulatory T-Cells Decrease Response To Donor Lymphocyte Infusions, Independent Of Graft Versus Host Disease In Multiple Myeloma

Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing

Host Dendritic Cell Vaccinations Combined with Donor Lymphocyte Infusions Induce Host and KLH Specific Immunity in Multiple Myeloma Patients.

Polychemotherapy in Combination with Thalidomide Followed by Autologous or Allogeneic Transplantation for Rescue after Autograft or Induction Therapy Failure in Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only